Tenaya Therapeutics (TNYA) Net Equity Issued and Repurchased (2020 - 2025)

Tenaya Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $104.2 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 122.73% year-over-year to $104.2 million in Q4 2025; TTM through Mar 2026 was $104.2 million, a 11295.08% increase from a year earlier, with the FY2025 full-year figure at $105.1 million, up 124.68% from the prior year.
• Net Equity Issued and Repurchased advanced to $104.2 million in Q4 2025 per TNYA's latest filing, from -$47.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $104.2 million in Q4 2025 and bottomed at -$47.9 million in Q3 2025.
• The 3-year median for Net Equity Issued and Repurchased is $20.0 million (2021), against an average of $19.1 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 202.41% in 2025; the steepest drop was 98.05% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at -$5000.0 in 2021, then jumped by 935340.0% to $46.8 million in 2024, then surged by 122.73% to $104.2 million in 2025.
• Per Business Quant, the three latest TNYA Net Equity Issued and Repurchased figures stand at $104.2 million (Q4 2025), -$47.9 million (Q3 2025), and $47.9 million (Q2 2025).